Proteins > Voltage-dependent L-type calcium channel subunit alpha-1C
Page last updated: 2024-08-07 17:06:46
Voltage-dependent L-type calcium channel subunit alpha-1C
A voltage-dependent L-type calcium channel subunit alpha-1C that is encoded in the genome of human. [PRO:WCB, UniProtKB:Q13936]
Synonyms
Calcium channel, L type, alpha-1 polypeptide, isoform 1, cardiac muscle;
Voltage-gated calcium channel subunit alpha Cav1.2
Research
Bioassay Publications (24)
Timeframe | Studies on this Protein(%) | All Drugs % |
pre-1990 | 2 (8.33) | 18.7374 |
1990's | 2 (8.33) | 18.2507 |
2000's | 2 (8.33) | 29.6817 |
2010's | 16 (66.67) | 24.3611 |
2020's | 2 (8.33) | 2.80 |
Compounds (103)
Drugs with Inhibition Measurements
Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
gallopamil | Homo sapiens (human) | IC50 | 0.0140 | 2 | 2 |
gallopamil | Homo sapiens (human) | Ki | 0.0054 | 1 | 1 |
phenytoin | Homo sapiens (human) | IC50 | 73.4500 | 2 | 2 |
tacrine | Homo sapiens (human) | IC50 | 17.0000 | 1 | 1 |
alfuzosin | Homo sapiens (human) | IC50 | 199.5260 | 1 | 1 |
amiodarone | Homo sapiens (human) | IC50 | 1.0850 | 2 | 2 |
amitriptyline | Homo sapiens (human) | IC50 | 11.6000 | 1 | 1 |
amlodipine | Homo sapiens (human) | IC50 | 2.7000 | 2 | 2 |
astemizole | Homo sapiens (human) | IC50 | 1.1000 | 1 | 1 |
bepridil | Homo sapiens (human) | IC50 | 1.2000 | 2 | 2 |
verapamil | Homo sapiens (human) | IC50 | 24.1417 | 6 | 6 |
chlorpromazine | Homo sapiens (human) | IC50 | 3.4000 | 1 | 1 |
cifenline | Homo sapiens (human) | IC50 | 30.0000 | 1 | 1 |
cilostazol | Homo sapiens (human) | IC50 | 91.2000 | 1 | 1 |
cisapride | Homo sapiens (human) | IC50 | 11.8000 | 1 | 1 |
clotrimazole | Homo sapiens (human) | IC50 | 0.5900 | 1 | 1 |
diazepam | Homo sapiens (human) | IC50 | 30.5000 | 1 | 1 |
disopyramide | Homo sapiens (human) | IC50 | 1,036.7000 | 1 | 1 |
donepezil | Homo sapiens (human) | IC50 | 34.3000 | 1 | 1 |
droperidol | Homo sapiens (human) | IC50 | 7.6000 | 1 | 1 |
flecainide | Homo sapiens (human) | IC50 | 27.1000 | 1 | 1 |
haloperidol | Homo sapiens (human) | IC50 | 1.5000 | 2 | 2 |
halothane | Homo sapiens (human) | IC50 | 8,150.0000 | 2 | 2 |
imipramine | Homo sapiens (human) | IC50 | 8.3000 | 1 | 1 |
1-methyl-3-isobutylxanthine | Homo sapiens (human) | IC50 | 466.0000 | 1 | 1 |
isradipine | Homo sapiens (human) | IC50 | 0.0022 | 1 | 1 |
lamotrigine | Homo sapiens (human) | IC50 | 1,421.9100 | 2 | 2 |
loratadine | Homo sapiens (human) | IC50 | 11.4000 | 1 | 1 |
methadone | Homo sapiens (human) | IC50 | 37.4000 | 1 | 1 |
metronidazole | Homo sapiens (human) | IC50 | 177.9000 | 1 | 1 |
mexiletine | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
mitoxantrone | Homo sapiens (human) | IC50 | 22.5000 | 1 | 1 |
nicardipine | Homo sapiens (human) | IC50 | 11.3167 | 3 | 3 |
nifedipine | Homo sapiens (human) | IC50 | 3.6995 | 6 | 6 |
nifedipine | Homo sapiens (human) | Ki | 0.0102 | 2 | 3 |
nimodipine | Homo sapiens (human) | IC50 | 4.7133 | 3 | 3 |
nisoldipine | Homo sapiens (human) | IC50 | 0.0030 | 1 | 1 |
nitrendipine | Homo sapiens (human) | IC50 | 0.0152 | 2 | 2 |
nitrendipine | Homo sapiens (human) | Ki | 0.0002 | 1 | 1 |
pentobarbital | Homo sapiens (human) | IC50 | 299.0000 | 1 | 1 |
procainamide | Homo sapiens (human) | IC50 | 389.5000 | 1 | 1 |
propranolol | Homo sapiens (human) | IC50 | 21.0000 | 1 | 1 |
risperidone | Homo sapiens (human) | IC50 | 79.6000 | 2 | 2 |
sotalol | Homo sapiens (human) | IC50 | 608.1500 | 2 | 2 |
terfenadine | Homo sapiens (human) | IC50 | 1.1250 | 2 | 2 |
thioridazine | Homo sapiens (human) | IC50 | 2.4100 | 2 | 2 |
trimethoprim | Homo sapiens (human) | IC50 | 34.0000 | 1 | 1 |
pimozide | Homo sapiens (human) | IC50 | 0.2010 | 2 | 2 |
terodiline | Homo sapiens (human) | IC50 | 4.8000 | 1 | 1 |
halofantrine | Homo sapiens (human) | IC50 | 1.9000 | 1 | 1 |
ribavirin | Homo sapiens (human) | IC50 | 622.5000 | 1 | 1 |
diltiazem | Homo sapiens (human) | IC50 | 15.0700 | 3 | 3 |
pinaverium | Homo sapiens (human) | IC50 | 1.7500 | 1 | 1 |
piperacillin | Homo sapiens (human) | IC50 | 1,226.0000 | 1 | 1 |
paroxetine | Homo sapiens (human) | IC50 | 3.9000 | 1 | 1 |
lidamidine | Homo sapiens (human) | IC50 | 30.0000 | 1 | 1 |
sertindole | Homo sapiens (human) | IC50 | 7.6000 | 2 | 2 |
sparfloxacin | Homo sapiens (human) | IC50 | 88.8000 | 1 | 1 |
mibefradil | Homo sapiens (human) | IC50 | 66.1863 | 6 | 6 |
ibutilide | Homo sapiens (human) | IC50 | 62.5000 | 1 | 1 |
lamivudine | Homo sapiens (human) | IC50 | 54.2000 | 1 | 1 |
duloxetine | Homo sapiens (human) | IC50 | 42.6396 | 3 | 3 |
nebivolol | Homo sapiens (human) | IC50 | 15.8489 | 1 | 1 |
uk 68798 | Homo sapiens (human) | IC50 | 317.0472 | 4 | 4 |
voriconazole | Homo sapiens (human) | IC50 | 414.2000 | 1 | 1 |
doripenem | Homo sapiens (human) | IC50 | 1.9953 | 1 | 1 |
tadalafil | Homo sapiens (human) | IC50 | 398.1070 | 1 | 1 |
paliperidone | Homo sapiens (human) | IC50 | 530.6690 | 3 | 3 |
moxifloxacin | Homo sapiens (human) | IC50 | 246.6690 | 3 | 3 |
solifenacin | Homo sapiens (human) | IC50 | 5.3048 | 2 | 2 |
telbivudine | Homo sapiens (human) | IC50 | 713.9000 | 1 | 1 |
cyc 202 | Homo sapiens (human) | IC50 | 23.4000 | 1 | 1 |
lapatinib | Homo sapiens (human) | IC50 | 8,922.0800 | 2 | 2 |
darunavir | Homo sapiens (human) | IC50 | 1,584.8900 | 1 | 1 |
deferasirox | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
lacosamide | Homo sapiens (human) | IC50 | 50.1187 | 1 | 1 |
quinidine | Homo sapiens (human) | IC50 | 13.1100 | 2 | 2 |
saquinavir | Homo sapiens (human) | IC50 | 1.9000 | 1 | 1 |
linezolid | Homo sapiens (human) | IC50 | 105.4000 | 1 | 1 |
mepirodipine | Homo sapiens (human) | IC50 | 2.1500 | 2 | 2 |
tolterodine | Homo sapiens (human) | IC50 | 25.1189 | 1 | 1 |
darifenacin | Homo sapiens (human) | IC50 | 1,584.8900 | 1 | 1 |
s 1033 | Homo sapiens (human) | IC50 | 1,122.1687 | 3 | 3 |
dasatinib | Homo sapiens (human) | IC50 | 243.4653 | 3 | 3 |
sitagliptin | Homo sapiens (human) | IC50 | 50,073.5500 | 2 | 2 |
np 118809 | Homo sapiens (human) | IC50 | 12.2000 | 1 | 1 |
cilnidipine | Homo sapiens (human) | IC50 | 9.0000 | 2 | 2 |
l 745870 | Homo sapiens (human) | IC50 | 9.0000 | 1 | 1 |
silodosin | Homo sapiens (human) | IC50 | 794.3280 | 1 | 1 |
su 11248 | Homo sapiens (human) | IC50 | 104.1196 | 3 | 3 |
ceftriaxone | Homo sapiens (human) | IC50 | 153.8000 | 1 | 1 |
alvimopan anhydrous | Homo sapiens (human) | IC50 | 5.0119 | 1 | 1 |
palonosetron | Homo sapiens (human) | IC50 | 398.1070 | 1 | 1 |
lu 208075 | Homo sapiens (human) | IC50 | 2,511.8900 | 1 | 1 |
ith 4012 | Homo sapiens (human) | IC50 | 20.0000 | 1 | 1 |
mk-3102 | Homo sapiens (human) | IC50 | 30.0000 | 2 | 2 |
raltegravir | Homo sapiens (human) | IC50 | 246.7000 | 1 | 1 |
mk-8825 | Homo sapiens (human) | IC50 | 20.0000 | 1 | 1 |
trv130 | Homo sapiens (human) | IC50 | 36.0000 | 1 | 1 |
ajmaline | Homo sapiens (human) | IC50 | 71.0000 | 1 | 1 |
clozapine | Homo sapiens (human) | IC50 | 3.6000 | 1 | 1 |
sildenafil | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
vardenafil | Homo sapiens (human) | IC50 | 133.5190 | 2 | 2 |
thiamet g | Homo sapiens (human) | IC50 | 30.0000 | 1 | 1 |
Drugs with Activation Measurements
Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
sumatriptan | Homo sapiens (human) | EC50 | 0.0120 | 1 | 1 |
l 772405 | Homo sapiens (human) | EC50 | 0.0008 | 1 | 1 |
Drugs with Other Measurements
Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
nifedipine | Homo sapiens (human) | ID50 | 0.0100 | 1 | 2 |
MICE models: superior to the HERG model in predicting Torsade de Pointes.Scientific reports, , Volume: 3, 2013
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.Journal of applied toxicology : JAT, , Volume: 32, Issue:10, 2012
Verapamil analogues with restricted molecular flexibility: synthesis and pharmacological evaluation of the four isomers of alpha-[1-[3-[N-[1- [2-(3,4-dimethoxyphenyl)ethyl]]-N-methylamino]cyclohexyl]]-alpha- isopropyl-3,4-dimethoxybenzene-acetonitrile.Journal of medicinal chemistry, , Feb-19, Volume: 36, Issue:4, 1993
New Dual Small Molecules for Alzheimer's Disease Therapy Combining Histamine HJournal of medicinal chemistry, , 12-26, Volume: 62, Issue:24, 2019
Dimeric isoxazolyl-1,4-dihydropyridines have enhanced binding at the multi-drug resistance transporter.Bioorganic & medicinal chemistry, , 06-15, Volume: 25, Issue:12, 2017
MICE models: superior to the HERG model in predicting Torsade de Pointes.Scientific reports, , Volume: 3, 2013
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.Journal of applied toxicology : JAT, , Volume: 32, Issue:10, 2012
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.Cardiovascular research, , Jul-01, Volume: 91, Issue:1, 2011
Diethyl 3,6-dihydro-2,4-dimethyl-2,6-methano-1,3-benzothiazocine-5,11- dicarboxylates as calcium entry antagonists: new conformationally restrained analogues of Hantzsch 1,4-dihydropyridines related to nitrendipine as probes for receptor-site conformationJournal of medicinal chemistry, , Volume: 30, Issue:4, 1987
Synthesis and calcium channel antagonist activity of dialkyl 1,4-dihydro-2,6-dimethyl-4-(pyridinyl)-3,5-pyridinedicarboxylates.Journal of medicinal chemistry, , Volume: 29, Issue:12, 1986
Structural Modifications of Nimodipine Lead to Novel PDE1 Inhibitors with Anti-pulmonary Fibrosis Effects.Journal of medicinal chemistry, , 06-23, Volume: 65, Issue:12, 2022
Polycyclic maleimide-based derivatives as first dual modulators of neuronal calcium channels and GSK-3β for Alzheimer's disease treatment.European journal of medicinal chemistry, , Feb-01, Volume: 163, 2019
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.Journal of applied toxicology : JAT, , Volume: 32, Issue:10, 2012
MICE models: superior to the HERG model in predicting Torsade de Pointes.Scientific reports, , Volume: 3, 2013
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.Cardiovascular research, , Jul-01, Volume: 91, Issue:1, 2011
Diethyl 3,6-dihydro-2,4-dimethyl-2,6-methano-1,3-benzothiazocine-5,11- dicarboxylates as calcium entry antagonists: new conformationally restrained analogues of Hantzsch 1,4-dihydropyridines related to nitrendipine as probes for receptor-site conformationJournal of medicinal chemistry, , Volume: 30, Issue:4, 1987
MICE models: superior to the HERG model in predicting Torsade de Pointes.Scientific reports, , Volume: 3, 2013
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.Journal of applied toxicology : JAT, , Volume: 32, Issue:10, 2012
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.Cardiovascular research, , Jul-01, Volume: 91, Issue:1, 2011
Discovery of a Potent, Selective T-type Calcium Channel Blocker as a Drug Candidate for the Treatment of Generalized Epilepsies.Journal of medicinal chemistry, , 12-14, Volume: 60, Issue:23, 2017
Discovery of novel bridged tetrahydronaphthalene derivatives as potent T/L-type calcium channel blockers.Bioorganic & medicinal chemistry letters, , Sep-15, Volume: 25, Issue:18, 2015
MICE models: superior to the HERG model in predicting Torsade de Pointes.Scientific reports, , Volume: 3, 2013
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.Journal of applied toxicology : JAT, , Volume: 32, Issue:10, 2012
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.Cardiovascular research, , Jul-01, Volume: 91, Issue:1, 2011
MICE models: superior to the HERG model in predicting Torsade de Pointes.Scientific reports, , Volume: 3, 2013
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.Journal of applied toxicology : JAT, , Volume: 32, Issue:10, 2012
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.Cardiovascular research, , Jul-01, Volume: 91, Issue:1, 2011
Prediction of Thorough QT study results using action potential simulations based on ion channel screens.Journal of pharmacological and toxicological methods, , Volume: 70, Issue:3
MICE models: superior to the HERG model in predicting Torsade de Pointes.Scientific reports, , Volume: 3, 2013
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.Journal of applied toxicology : JAT, , Volume: 32, Issue:10, 2012
Prediction of Thorough QT study results using action potential simulations based on ion channel screens.Journal of pharmacological and toxicological methods, , Volume: 70, Issue:3
Structure-activity-relationship of amide and sulfonamide analogs of omarigliptin.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 25, Issue:24, 2015
Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes.Journal of medicinal chemistry, , Apr-24, Volume: 57, Issue:8, 2014
Enables
This protein enables 8 target(s):
Target | Category | Definition |
voltage-gated calcium channel activity | molecular function | Enables the transmembrane transfer of a calcium ion by a voltage-gated channel. A voltage-gated channel is a channel whose open state is dependent on the voltage across the membrane in which it is embedded. [GOC:mtg_transport, GOC:tb, ISBN:0815340729] |
protein binding | molecular function | Binding to a protein. [GOC:go_curators] |
calmodulin binding | molecular function | Binding to calmodulin, a calcium-binding protein with many roles, both in the calcium-bound and calcium-free states. [GOC:krc] |
high voltage-gated calcium channel activity | molecular function | Enables the transmembrane transfer of a calcium ion by a high voltage-gated channel. A high voltage-gated channel is a channel whose open state is dependent on high voltage across the membrane in which it is embedded. [GOC:mtg_transport, ISBN:0815340729, PMID:16382099] |
metal ion binding | molecular function | Binding to a metal ion. [GOC:ai] |
alpha-actinin binding | molecular function | Binding to alpha-actinin, one of a family of proteins that cross-link F-actin as antiparallel homodimers. Alpha-actinin has a molecular mass of 93-103 KDa; at the N-terminus there are two calponin homology domains, at the C-terminus there are two EF-hands. These two domains are connected by the rod domain. This domain is formed by triple-helical spectrin repeats. [PMID:10984498, PMID:11699871, PMID:15014165] |
voltage-gated calcium channel activity involved in cardiac muscle cell action potential | molecular function | Enables the transmembrane transfer of a calcium ion by a voltage-gated channel across the plasma membrane of a cardiac muscle cell that contributes to the depolarization phase of an action potential. A voltage-gated channel is a channel whose open state is dependent on the voltage across the membrane in which it is embedded. [GOC:BHF, GOC:mtg_cardiac_conduct_nov11] |
voltage-gated calcium channel activity involved in AV node cell action potential | molecular function | Enables the transmembrane transfer of a calcium ion by a voltage-gated channel across the plasma membrane of an AV node cardiac muscle cell that contributes to the depolarization phase of an action potential. A voltage-gated channel is a channel whose open state is dependent on the voltage across the membrane in which it is embedded. [GOC:BHF, GOC:mtg_cardiac_conduct_nov11] |
Located In
This protein is located in 8 target(s):
Target | Category | Definition |
cytoplasm | cellular component | The contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures. [ISBN:0198547684] |
plasma membrane | cellular component | The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. [ISBN:0716731363] |
postsynaptic density | cellular component | An electron dense network of proteins within and adjacent to the postsynaptic membrane of an asymmetric, neuron-neuron synapse. Its major components include neurotransmitter receptors and the proteins that spatially and functionally organize them such as anchoring and scaffolding molecules, signaling enzymes and cytoskeletal components. [GOC:BHF, GOC:dos, GOC:ef, GOC:jid, GOC:pr, GOC:sjp, http://molneuro.kaist.ac.kr/psd, PMID:14532281, Wikipedia:Postsynaptic_density] |
membrane | cellular component | A lipid bilayer along with all the proteins and protein complexes embedded in it and attached to it. [GOC:dos, GOC:mah, ISBN:0815316194] |
Z disc | cellular component | Platelike region of a muscle sarcomere to which the plus ends of actin filaments are attached. [GOC:mtg_muscle, ISBN:0815316194] |
dendrite | cellular component | A neuron projection that has a short, tapering, morphology. Dendrites receive and integrate signals from other neurons or from sensory stimuli, and conduct nerve impulses towards the axon or the cell body. In most neurons, the impulse is conveyed from dendrites to axon via the cell body, but in some types of unipolar neuron, the impulse does not travel via the cell body. [GOC:aruk, GOC:bc, GOC:dos, GOC:mah, GOC:nln, ISBN:0198506732] |
perikaryon | cellular component | The portion of the cell soma (neuronal cell body) that excludes the nucleus. [GOC:jl] |
postsynaptic density membrane | cellular component | The membrane component of the postsynaptic density. This is the region of the postsynaptic membrane in which the population of neurotransmitter receptors involved in synaptic transmission are concentrated. [GOC:dos] |
Part Of
This protein is part of 2 target(s):
Target | Category | Definition |
L-type voltage-gated calcium channel complex | cellular component | A type of voltage-dependent calcium channel responsible for excitation-contraction coupling of skeletal, smooth, and cardiac muscle. 'L' stands for 'long-lasting' referring to the length of activation. [GOC:ame, PMID:12946355] |
voltage-gated calcium channel complex | cellular component | A protein complex that forms a transmembrane channel through which calcium ions may pass in response to changes in membrane potential. [GOC:mah] |
Involved In
This protein is involved in 20 target(s):
Target | Category | Definition |
immune system development | biological process | The process whose specific outcome is the progression of an organismal system whose objective is to provide calibrated responses by an organism to a potential internal or invasive threat, over time, from its formation to the mature structure. A system is a regularly interacting or interdependent group of organs or tissues that work together to carry out a given biological process. [GOC:add, GOC:dph] |
positive regulation of cytosolic calcium ion concentration | biological process | Any process that increases the concentration of calcium ions in the cytosol. [GOC:ai] |
heart development | biological process | The process whose specific outcome is the progression of the heart over time, from its formation to the mature structure. The heart is a hollow, muscular organ, which, by contracting rhythmically, keeps up the circulation of the blood. [GOC:jid, UBERON:0000948] |
regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion | biological process | Any process that modulates the frequency, rate or extent of cardiac muscle contraction via the regulation of the release of sequestered calcium ion by sarcoplasmic reticulum into cytosol. The sarcoplasmic reticulum is the endoplasmic reticulum of striated muscle, specialised for the sequestration of calcium ions that are released upon receipt of a signal relayed by the T tubules from the neuromuscular junction. [GOC:BHF, GOC:dph, GOC:tb] |
embryonic forelimb morphogenesis | biological process | The process, occurring in the embryo, by which the anatomical structures of the forelimb are generated and organized. The forelimbs are the front limbs of an animal, e.g. the arms of a human. [ISBN:0198612001] |
camera-type eye development | biological process | The process whose specific outcome is the progression of the camera-type eye over time, from its formation to the mature structure. The camera-type eye is an organ of sight that receives light through an aperture and focuses it through a lens, projecting it on a photoreceptor field. [GOC:go_curators, GOC:mtg_sensu] |
positive regulation of adenylate cyclase activity | biological process | Any process that activates or increases the frequency, rate or extent of adenylate cyclase activity. [GOC:go_curators] |
positive regulation of muscle contraction | biological process | Any process that activates or increases the frequency, rate or extent of muscle contraction. [GOC:go_curators] |
calcium ion transport into cytosol | biological process | The directed movement of calcium ions (Ca2+) into the cytosol. [GOC:dph, GOC:tb] |
cardiac conduction | biological process | Transfer of an organized electrical impulse across the heart to coordinate the contraction of cardiac muscles. The process begins with generation of an action potential (in the sinoatrial node (SA) in humans) and ends with a change in the rate, frequency, or extent of the contraction of the heart muscles. [GOC:dph] |
calcium ion transmembrane transport via high voltage-gated calcium channel | biological process | A process in which a calcium ion is transported from one side of a membrane to the other by means of a high voltage-gated calcium channel. [GOC:dph] |
calcium ion transmembrane transport | biological process | A process in which a calcium ion is transported from one side of a membrane to the other by means of some agent such as a transporter or pore. [GOC:mah] |
cardiac muscle cell action potential involved in contraction | biological process | An action potential that occurs in a cardiac muscle cell and is involved in its contraction. [GOC:BHF, GOC:mtg_cardiac_conduct_nov11] |
membrane depolarization during cardiac muscle cell action potential | biological process | The process in which cardiac muscle cell membrane potential changes in the depolarizing direction from the negative resting potential towards the positive membrane potential that will be the peak of the action potential. [GOC:BHF, GOC:mtg_cardiac_conduct_nov11] |
membrane depolarization during AV node cell action potential | biological process | The process in which AV node cardiac muscle cell membrane potential changes in the depolarizing direction from the negative resting potential towards the positive membrane potential that will be the peak of the action potential. [GOC:BHF, GOC:mtg_cardiac_conduct_nov11] |
cell communication by electrical coupling involved in cardiac conduction | biological process | The process that mediates signaling interactions between one cell and another cell by transfer of current between their adjacent cytoplasms via intercellular protein channels and contributes to the process of cardiac conduction. [GOC:BHF, GOC:mtg_cardiac_conduct_nov11] |
regulation of heart rate by cardiac conduction | biological process | A cardiac conduction process that modulates the frequency or rate of heart contraction. [GOC:BHF, GOC:mtg_cardiac_conduct_nov11] |
regulation of ventricular cardiac muscle cell action potential | biological process | Any process that modulates the frequency, rate or extent of action potential creation, propagation or termination in a ventricular cardiac muscle cell contributing to the regulation of its contraction. This typically occurs via modulation of the activity or expression of voltage-gated ion channels. [GOC:BHF, GOC:mtg_cardiac_conduct_nov11] |
membrane depolarization during atrial cardiac muscle cell action potential | biological process | The process in which atrial cardiac muscle cell membrane potential changes in the depolarizing direction from the negative resting potential towards the positive membrane potential that will be the peak of the action potential. [GOC:dph, GOC:mtg_cardiac_conduct_nov11, GOC:tb] |
calcium ion import across plasma membrane | biological process | The directed movement of calcium ions from outside of a cell, across the plasma membrane and into the cytosol. [GOC:dos] |